Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.

[1]  Yusuf A. Hannun,et al.  Regulation of protein kinase C and role in cancer biology , 1994, Cancer and Metastasis Reviews.

[2]  E. Eisenhauer,et al.  Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  C. Rudin,et al.  Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  S. Crooke.  Antisense Drug Technology , 2001 .

[5]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[6]  J. Nemunaitis,et al.  Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  B. Sikic,et al.  Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  T. Mikkelsen,et al.  The role of protein kinase Cα in U-87 glioma invasion , 1999, International Journal of Developmental Neuroscience.

[9]  B. Snaar-Jagalska,et al.  Signal perception and transduction: the role of protein kinases. , 1999, Biochimica et biophysica acta.

[10]  N. Dean,et al.  Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha. , 1998, Cancer letters.

[11]  S. Yuspa,et al.  The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. , 1998, Journal of dermatological science.

[12]  J. Nalbantoglu,et al.  Differential role for protein kinase C-mediated signaling in the proliferation of medulloblastoma cell lines. , 1998, International journal of oncology.

[13]  P. Vihko,et al.  The protein kinase C activator, phorbol ester, elicits disparate functional responses in androgen-sensitive and androgen-independent human prostatic cancer cells. , 1998, Biochemical and biophysical research communications.

[14]  R. Martuza,et al.  Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. , 1996, Molecular pharmacology.

[15]  C. F. Bennett,et al.  Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.

[16]  P. Parker,et al.  MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. , 1995, The Journal of clinical investigation.

[17]  D. Porro,et al.  Involvement of the alpha isoenzyme of protein kinase C in the growth inhibition induced by phorbol esters in MH1C1 hepatoma cells. , 1994, Biochemical and biophysical research communications.

[18]  N. Dean,et al.  Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  N. Dean,et al.  Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. , 1994, The Journal of biological chemistry.

[20]  S. Yuspa.  The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis--thirty-third G. H. A. Clowes Memorial Award Lecture. , 1994, Cancer research.

[21]  A. Basu,et al.  The potential of protein kinase C as a target for anticancer treatment. , 1993, Pharmacology & therapeutics.

[22]  S. Crooke.  Therapeutic Applications of Oligonucleotides , 1992, Bio/Technology.

[23]  B. Calabretta,et al.  Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. , 1991, Cancer research.

[24]  J. Toulmé,et al.  Specific regulation of gene expression by antisense, sense and antigene nucleic acids. , 1990, Biochimica et biophysica acta.

[25]  S. Singletary,et al.  Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. , 1989, Cancer research.

[26]  Y. Nishizuka,et al.  The molecular heterogeneity of protein kinase C and its implications for cellular regulation , 1988, Nature.